KOKatalin Osz

Katalin Osz

*This is an algorithmically generated author record based on publicly available information.

Katalin Osz has a total of 13 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Supplementary Tables S1-S2 from Timing Genomic Antigen Loss in Multiple Myeloma Treated with T Cell–Redirecting Immunotherapies

    by Marios Papadimitriou, Sungwoo Ahn, Benjamin T. Diamond, Holly Lee, John B. McIntyre, Marietta Truger, Michael A. Durante, Bachisio Ziccheddu, Katalin Osz, Ola Landgren, et al.

    Table S1: Clinical and sample data for patients in the study cohort. Table S2: GPRC5D and TNFRSF17 mutations from baseline samples in the CoMMpass dataset.

  • Open Access

    Data from Timing Genomic Antigen Loss in Multiple Myeloma Treated with T Cell–Redirecting Immunotherapies

    by Marios Papadimitriou, Sungwoo Ahn, Benjamin T. Diamond, Holly Lee, John B. McIntyre, Marietta Truger, Michael A. Durante, Bachisio Ziccheddu, Katalin Osz, Ola Landgren, et al.

    Genomic antigen loss is a recurring mechanism of resistance to chimeric antigen receptor T-cell (CAR-T) and T-cell engagers (TCE) in relapsed/refractory multiple myeloma (RRMM). Yet, it remains unclear whether these events are acquired under treatment or merely selected from preexisting, undetectable clones. By leveraging chemotherapy mutational signatures as temporal barcodes within whole-genome sequencing data, we could time genomic antigen escape in 4 of 11 patients with RRMM. In all cases, the biallelic loss was driven by genomic events acquired after exposure to BCMA- and GPCR5D-targeted CAR-T/TCE and not present at baseline. Longitudinal digital PCR analysis corroborated that resistance mutations were undetectable at therapy initiation but emerged preceding relapse. Among 752 newly diagnosed patients, only 2.7% and 9% had monoallelic inactivation of TNFRSF17 and GPCR5D, respectively, with no biallelic loss. Our findings suggest limited utility of mutational screening prior to CAR-T/TCE while underscoring the importance of dynamic surveillance during therapy.Significance:Multiple myeloma has been demonstrated to recurrently develop resistance to T-cell redirection via genomic antigen escape. By leveraging chemotherapy mutational signatures, we demonstrate that somatic antigen-escape mechanisms are uniformly acquired following treatment initiation and not selected from among preexisting clones, emphasizing the importance of dynamic longitudinal surveillance for their emergence.See related commentary by Kauer et al., p. 532

  • Open Access

    Supplementary Figures S1-S3 from Timing Genomic Antigen Loss in Multiple Myeloma Treated with T Cell–Redirecting Immunotherapies

    by Marios Papadimitriou, Sungwoo Ahn, Benjamin T. Diamond, Holly Lee, John B. McIntyre, Marietta Truger, Michael A. Durante, Bachisio Ziccheddu, Katalin Osz, Ola Landgren, et al.

    Supplemental Figure 1: Swimmer plot of all cases described in the manuscript. Supplemental Figure 2: The 96-mutational profile of the truncal mutations per each of patients that can be timed, revealing a distinct, clonal melphalan signature profile (SBS-MM1/SBS99). Supplemental Figure 3: Additional Cases for which antigen escape timing was not possible.

  • Timing Genomic Antigen Loss in Multiple Myeloma Treated with T Cell–Redirecting Immunotherapies

    by Marios Papadimitriou, Sungwoo Ahn, Benjamin T. Diamond, Holly Lee, John B. McIntyre, Marietta Truger, Michael A. Durante, Bachisio Ziccheddu, Katalin Osz, Ola Landgren, et al.

    Genomic antigen loss is a recurring mechanism of resistance to chimeric antigen receptor T-cell (CAR-T) and T-cell engagers (TCE) in relapsed/refractory multiple myeloma (RRMM). Yet, it remains unclear whether these events are acquired under treatment or merely selected from preexisting, undetectable clones. By leveraging chemotherapy mutational signatures as temporal barcodes within whole-genome sequencing data, we could time genomic antigen escape in 4 of 11 patients with RRMM. In all cases, the biallelic loss was driven by genomic events acquired after exposure to BCMA- and GPCR5D-targeted CAR-T/TCE and not present at baseline. Longitudinal digital PCR analysis corroborated that resistance mutations were undetectable at therapy initiation but emerged preceding relapse. Among 752 newly diagnosed patients, only 2.7% and 9% had monoallelic inactivation of TNFRSF17 and GPCR5D, respectively, with no biallelic loss. Our findings suggest limited utility of mutational screening prior to CAR-T/TCE while underscoring the importance of dynamic surveillance during therapy. Significance: Multiple myeloma has been demonstrated to recurrently develop resistance to T-cell redirection via genomic antigen escape. By leveraging chemotherapy mutational signatures, we demonstrate that somatic antigen-escape mechanisms are uniformly acquired following treatment initiation and not selected from among preexisting clones, emphasizing the importance of dynamic longitudinal surveillance for their emergence. See related commentary by Kauer et al., p. 532